Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carl H June

Showing results (271-280 of 460) with videos related to

Pageof 46
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 25, 2002
A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapySteven G Deeks, Bridget Wagner, Peter A Anton, et al.
Blood Advances|December 10, 2025
CAR T cells targeting C-C motif chemokine receptor 4 (CCR4) selectively deplete human Tregs ex vivo and in vivoCaitlin M Tilsed, Karen P Fong, Xinyi Shi, et al.
Cancer Immunology Research|April 30, 2014
Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicityLiang-Chuan S Wang, Albert Lo, John Scholler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2022
Monitoring Therapeutic Response to Anti-FAP CAR T Cells Using [18F]AlF-FAPI-74Iris K Lee, Estela Noguera-Ortega, Zebin Xiao, et al.
Blood|November 5, 2005
A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulationDavid L Porter, Bruce L Levine, Nancy Bunin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2014
Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumorsEdmund K Moon, Liang-Chuan Wang, Douglas V Dolfi, et al.
Biorxiv : the Preprint Server for Biology|April 24, 2023
Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumorsZebin Xiao, Leslie Todd, Li Huang, et al.
Blood Advances|May 12, 2023
CD38 as a pan-hematologic target for chimeric antigen receptor T cellsTina Glisovic-Aplenc, Caroline Diorio, John A Chukinas, et al.
Nature Communications|August 22, 2023
Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumorsZebin Xiao, Leslie Todd, Li Huang, et al.
Critical Care Medicine|September 16, 2016
Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic LeukemiaJulie C Fitzgerald, Scott L Weiss, Shannon L Maude, et al.
Pageof 46

Showing results (271-280 of 460) with videos related to

Sort By:
Pageof 46
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 25, 2002
A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapySteven G Deeks, Bridget Wagner, Peter A Anton, et al.
Blood Advances|December 10, 2025
CAR T cells targeting C-C motif chemokine receptor 4 (CCR4) selectively deplete human Tregs ex vivo and in vivoCaitlin M Tilsed, Karen P Fong, Xinyi Shi, et al.
Cancer Immunology Research|April 30, 2014
Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicityLiang-Chuan S Wang, Albert Lo, John Scholler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2022
Monitoring Therapeutic Response to Anti-FAP CAR T Cells Using [18F]AlF-FAPI-74Iris K Lee, Estela Noguera-Ortega, Zebin Xiao, et al.
Blood|November 5, 2005
A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulationDavid L Porter, Bruce L Levine, Nancy Bunin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2014
Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumorsEdmund K Moon, Liang-Chuan Wang, Douglas V Dolfi, et al.
Biorxiv : the Preprint Server for Biology|April 24, 2023
Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumorsZebin Xiao, Leslie Todd, Li Huang, et al.
Blood Advances|May 12, 2023
CD38 as a pan-hematologic target for chimeric antigen receptor T cellsTina Glisovic-Aplenc, Caroline Diorio, John A Chukinas, et al.
Nature Communications|August 22, 2023
Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumorsZebin Xiao, Leslie Todd, Li Huang, et al.
Critical Care Medicine|September 16, 2016
Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic LeukemiaJulie C Fitzgerald, Scott L Weiss, Shannon L Maude, et al.
Pageof 46